The project aims to develop an innovative colorectal cancer model that integrates a large bioprinted colorectal cancer organoid and the vascular system that nurtures it inside a microfluidic chip. This innovative model will have ground-breaking applications in pharmaceutical research and biomedicine, paving the way towards the application of in vitro models in personalized medicine starting where it is most needed, oncology.

The general objective of DIAMOOC is the generation of a robust in vitro platform for the evaluation of drugs used in colorectal cancer treatment. This platform overcomes the main drawbacks of patient-derived organoid research to date: the lack of a vascular network and immune system activity in the organoid microenvironment.

In order to accomplish this objective, DIAMOOC integrates different fields of research, forming a multidisciplinary consortium that combines experience and knowledge in machine learning and artificial intelligence, bioprinting, biological simulation, microfluidic engineering and biomedicine.

Beonchip will be responsible in the DIAMOOC Project for the design and fabrication of microfluidic platforms compatible with bioprinting for the culture of large Organoids in Chip.

The objective of DIAMOOC is to utilize microfluidic technology for the creation of an organ-on-chip platform capable of hosting large-sized organoids and embedding them in a perfusable vascular system. This system will simultaneously enable the application of immune system activity on the organoid and the realistic application of drugs. With this, DIAMOOC aims to break down the barriers to the use of organoids in regulatory testing and pharmaceutical research.